Mereo BioPharma Group plc is a biopharmaceutical company focused on the development of therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). In addition to the rare disease programs, it has two oncology product candidates in clinical development. Etigilimab is an IgG1 monoclonal antibody which binds to the human T-cell immunoreceptor with Ig and ITIM domains (TIGIT) receptor on immune cells to improve the activation and effectiveness of T-cell and NK cell antitumor activity. Navicixizumab is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Navicixizumab is developed for the treatment of late line ovarian cancer.
Código da empresaMREO
Nome da EmpresaMereo BioPharma Group PLC
Data de listagemJun 09, 2016
Fundado em2015
CEODr. Denise V. Scots-Knight, Ph.D.
Número de funcionários36
Tipo de títulosDepository Receipt
Fim do ano fiscalJun 09
EndereçoOne Cavendish Place
CidadeLONDON
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited Kingdom
Código postalW1G0QF
Telefone443330237300
Sitehttps://www.mereobiopharma.com/
Código da empresaMREO
Data de listagemJun 09, 2016
Fundado em2015
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.

Sem dados